Purchase this article with an account.
Shuzo Kaneda, Dai Miyazaki, Shin-ichi Sasaki, Keiko Yakura, Yuki Terasaka, Ken-ichiro Miyake, Yoshifumi Ikeda, Taisaku Funakoshi, Takashi Baba, Atsushi Yamasaki, Yoshitsugu Inoue; Multivariate Analyses of Inflammatory Cytokines in Eyes with Branch Retinal Vein Occlusion: Relationships to Bevacizumab Treatment. Invest. Ophthalmol. Vis. Sci. 2011;52(6):2982-2988. doi: 10.1167/iovs.10-6299.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To characterize the differential expression of intraocular inflammatory cytokines in eyes with branch retinal vein occlusion (BRVO) and to assess their roles as prognostic determinants of BRVO.
A prospective cohort study of 38 eyes with BRVO. Aqueous humor samples were collected just before the intravitreal injection of bevacizumab and were assessed for 18 cytokines, chemokines, and growth factors. For control, aqueous humor was collected from 28 eyes before cataract surgery.
In the aqueous of eyes with BRVO, the IL-23, IL-8, IL-6, IL-15, IL-12, and IL-17 levels were significantly higher than that in control eyes. Pretreatment visual acuity was significantly correlated with the concentrations of IL-8, IL-10, IL-2, IL-1β, IL-5, IL-6, IL-23, IL-4, MCP-1, IL-1α, IL-12, IL-13, IFN-γ, and IL-15. The pretreatment nonperfused area (NPA) was significantly correlated with the concentrations of IL-8, IL-2, MCP-1, and IL-6. Logistic regression analyses revealed significant associations between the BRVO and the concentrations of IL-8, IL-23, IL-12, IL-15, IL-10, IL-1β, and IL-13. IL-8 had the highest odds ratio (OR) and was significantly associated with NPA, central retinal thickness (CRT), and visual acuity. Bevacizumab treatment significantly improved visual acuity and CRT after 1 month. Refractoriness to bevacizumab (defined as CRT recovery 1 month after treatment by <90%) was significantly associated with the IL-12 level.
Of the induced cytokines in eyes with BRVO, IL-8 was the most significantly associated with the disease parameters of BRVO. IL-12 is most likely a factor that blocks the effect of bevacizumab treatment. (www.umin.ac.jp/ctr number, UMIN000003854.)
This PDF is available to Subscribers Only